A Phase 3 interventional study of Abatacept and Methotrexate in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 73 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-14.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 26 in phase 3, and was the 24th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 511 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2010, is one of 22 in phase 3, and was the 37th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission following 6 months of drug withdrawal.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
Drug: Abatacept · Drug: Methotrexate
Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
Drug: Methotrexate · Drug: Abatacept placebo
Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
Drug: Abatacept · Drug: Methotrexate placebo
Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
Also known as: Orencia, BMS 188667
Tablets, oral, 2.5 mg, once weekly, 12 months
Also known as: Rheumatrex
Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18
DAS28-CRP remission defined as \<2.6; TP=treatment phase; WP=withdrawal phase. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Time frame: Randomization to Months 12 and 18
Percentage of Participants Who Received Monotherapy and Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18
TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Time frame: Randomization to Months 12 and 18
Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time - Intent to Treat Population
TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Time frame: Randomization to Month 24
Adjusted Mean Change From Baseline in Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) at Months 6, 12, and 18
TP=treatment period; WP=withdrawal period. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Time frame: Baseline to Month 18
Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) at Months 12 and 18
TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity.
Time frame: Randomization to Month 18
Adjusted Mean Change From Baseline in Scores on Simplified Disease Activity Index (SDAI) Over Time
TP=treatment period; WP=withdrawal period. The SDAI is the simple linear sum of 5 outcome parameters: swollen joint count (SJC) and tender joint count (TJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SJC is assessed and recorded at each visit, with no swelling=0, swelling=1 (higher score indicates greater swelling). TJC is assessed at each visit through identification of joints that are painful under pressure or to passive motion, with no tenderness=0, tenderness=1 (higher score indicates greater affection due to disease activity)..
Time frame: Randomization to Month 18
Percentage of Participants Achieving a Health Assessment Questionnaire (HAQ) Response Over Time
HAQ response defined as a reduction of at least 0.3 units from baseline in score on the Health Assessment Questionnaire Disability Index (HAQ-DI), which assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.
Time frame: Randomization to Month 24
Adjusted Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Over Time
The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.
Time frame: Randomization to Month 18
Adjusted Mean Change From Baseline at Months 6, 12, and 18 in Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of Short Form-36 (SF-36)
TP=treatment period; WP=withdrawal period. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life (QOL) and comprises 8 domains, including 4 physical (physical health, bodily pain, physical functioning and physical role limitations) and 4 mental (mental health, vitality, social functioning, and emotional role limitation) subscales. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QOL (0=Poorest Health; 100=Best Health). Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
Time frame: Randomization to Months 6, 12, and 18
Adjusted Mean Change From Baseline Over Time in Findings on Magnetic Resonance Imaging (MRI)
TP=treatment period; WP=withdrawal period. Change from Baseline=Postbaseline-baseline value. MRI was used to assess joint damage progression at Months 6, 12, and 18. If \>20% of joints with a missing score for a parameter (erosion, osteitis, and synovitis), the MRI score of each parameter was considered missing. If ≤20% of joints had a missing score for a parameter, the MRI score for that parameter from the missing joints was carried forward from the previous MRI assessment, or carried backward from the next MRI assessment, if missing score occurred at baseline. MRI total score ranged from 0 (best outcome) to 4 (worst outcome). A gadolinium-enhanced MRI of the dominant hand-wrist was performed on all randomized patients at 5 points. The hand/wrist assessed to have more synovitis was selected initially and used for all subsequent evaluations. The MRI examination was standardized to ensure sufficient image quality for the evaluation of radiographic progression of rheumatoid arthritis.
Time frame: Randomization to Month 18
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Related Adverse Events (AEs), and Discontinuations Due to AEs During the Treatment Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.
Time frame: Day 1 to up to 56 days following the last dosing day (Day 365); all deaths during study period, including those that occurred >56 days after last dose in Treatment Period
Adverse Events (AEs) of Interest During the Treatment Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. AEs of special interest are events potentially associated with the drug or disease under study.
Time frame: Day 1 to 56 days following last dosing day (Day 365)
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality During Treatment Period
Lower limit of normal (LLN); Upper limit of normal (ULN); Pretreatment (preRX). Criteria for marked abnormality: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.
Time frame: Day 1 up to 56 days following the last dosing day in the Treatment Period (Day 365)
Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time During Withdrawal Period- Treated Participants in Remission at Month 12
WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.). Percentage= number of participants with remission divided by number of participants who were analyzed (all treated participants who were in remission at end of treatment period and entered the Withdrawal Period)
Time frame: End of Treatment Period (Month 12) to End of Withdrawal Period (Month 24)
Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) Over Time in Treatment Period and Withdrawal Period
TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity. Percent=number with remission/number evaluated (ITT)
Time frame: Randomization to Month 24
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs) and Discontinuations Due to AEs During the Full Study (All Periods)
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Includes data up to last active dose date +56 days if the participant discontinued the Treatment Period or did not enter the Withdrawal Period, up to the day of discontinuation in the Withdrawal Period for participants discontinuing the Withdrawal Period without entering the Re-exposure Period (RP), up to Day 729 visit (Month 24) for participants who complete the Withdrawal Period, and up to 56 days post last active dose in Re-exposure Period for participants entering the Re-exposure Period.
Time frame: Day 1 to 56 days post last dose in the study, up to Month 30
Adverse Events (AEs) of Interest During the Withdrawal Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes events with an onset date on or after 57 days post last dosing day (active abatacept or active MTX whichever is the later) in the Treatment Period and up to end of Withdrawal Period. Treatment groups represent treatment received during the Treatment Period.
Time frame: Last dose in TP + 57 days, up to Month 24
Adverse Events (AEs) of Interest During the Re-exposure Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes data up to 56 days post the last dosing day (active abatacept or active MTX, whichever is the later) in the Re-exposure Period. Treatment groups represent Treatment received during Treatment Period.
Time frame: First dose in Re-exposure period up to last dose of Re-exposure Period + 56 days
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Withdrawal Period
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase (GGT) (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.
Time frame: Last dose in TP + 57 days, up to Month 24
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Re-exposure Period
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.
Time frame: Start of re-exposure period to 56 days post last dose, up to Month 30
| Milestone | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Started | 119 | 116 | 116 |
| Completed | 103 | 91 | 96 |
| Not completed | 16 | 25 | 20 |
| Withdrew: Adverse event | 5 | 8 | 5 |
| Withdrew: Withdrawal by subject | 4 | 9 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Poor compliance/noncompliance | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 6 | 11 |
| Milestone | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Started | 84 | 66 | 75 |
| Completed | 14 | 10 | 17 |
| Not completed | 70 | 56 | 58 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 |
| Withdrew: Pregnancy | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: No longer met study criteria | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 65 | 54 | 53 |
| Withdrew: Non-specified | 0 | 1 | 1 |
| Milestone | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Started | 55 | 48 | 43 |
| Completed | 54 | 46 | 40 |
| Not completed | 1 | 2 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
DAS28-CRP remission defined as \<2.6; TP=treatment phase; WP=withdrawal phase. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
| Percentage of participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|
| Month 12 (TP Day 365) (n=115, 115) | 60.9 | 45.2 |
| Both Months 12 & 18 (WP Day 169) (n=115, 115) | 14.8 | 7.8 |
TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
| Percentage of participants | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|
| At Month 12 (TP Day 365) (n=113, 115) | 42.5 (33.36 to 51.59) | 45.2 (36.12 to 54.31) |
| At both Months 12 &18 (WP Day 169) (n=113, 115) | 12.4 (6.31 to 18.46) | 7.8 (2.92 to 12.73) |
TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
| Percentage of participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| TP Day 29 | 13.4 (7.32 to 19.57) | 8.6 (3.51 to 13.73) | 6.0 (1.70 to 10.37) |
| TP Day 57 | 24.4 (16.66 to 32.08) | 11.2 (5.47 to 16.95) | 9.5 (4.15 to 14.81) |
| TP Day 85 | 36.1 (27.50 to 44.77) | 21.6 (14.07 to 29.03) | 17.2 (10.37 to 24.12) |
| TP Day 113 | 37.8 (29.10 to 46.53) | 29.3 (21.03 to 37.59) | 19.0 (11.83 to 26.10) |
| TP Day 141 | 45.4 (36.43 to 54.32) | 29.3 (21.03 to 37.59) | 25.0 (17.12 to 32.88) |
| TP Day 169 | 45.4 (36.43 to 54.32) | 32.8 (24.22 to 41.30) | 26.7 (18.67 to 34.78) |
| TP Day 197 | 52.1 (43.13 to 61.08) | 36.2 (27.46 to 44.95) | 25.9 (17.89 to 33.83) |
| TP Day 225 | 57.1 (48.25 to 66.03) | 40.5 (31.58 to 49.45) | 30.2 (21.82 to 38.53) |
| TP Day 253 | 62.2 (53.47 to 70.90) | 37.9 (29.10 to 46.76) | 30.2 (21.82 to 38.53) |
| TP 281 | 51.3 (42.28 to 60.24) | 42.2 (33.25 to 51.23) | 32.8 (24.22 to 41.30) |
| TP 309 | 56.3 (47.39 to 65.21) | 37.9 (29.10 to 46.76) | 36.2 (27.46 to 44.95) |
| TP Day 337 | 63.0 (54.35 to 71.70) | 43.1 (34.09 to 52.12) | 33.6 (25.02 to 42.22) |
| TP 365 | 61.3 (52.60 to 70.09) | 43.1 (34.09 to 52.12) | 45.7 (36.62 to 54.75) |
| WP Day 29 | 51.3 (42.28 to 60.24) | 36.2 (27.46 to 44.95) | 27.6 (19.45 to 35.72) |
| WP Day 57 | 40.3 (31.52 to 49.15) | 25.0 (17.12 to 32.88) | 18.1 (11.10 to 25.11) |
| WP Day 85 | 31.1 (22.78 to 39.41) | 18.1 (11.10 to 25.11) | 18.1 (11.10 to 25.11) |
| WP Day 169 | 19.3 (12.23 to 26.42) | 12.9 (6.82 to 19.04) | 9.5 (4.15 to 14.81) |
| WP Day 253 | 17.6 (10.80 to 24.50) | 9.5 (4.15 to 14.81) | 13.8 (7.52 to 20.07) |
| WP Day 365 | 9.2 (4.04 to 14.45) | 6.0 (1.70 to 10.37) | 6.0 (1.70 to 10.37) |
TP=treatment period; WP=withdrawal period. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
| Units on a scale | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Month 6 (TP Day 169) (n=102, 96, 101) | -2.72 ± 0.12 | -2.33 ± 0.12 | -1.93 ± 0.12 |
| Month 12 (TP Day 365) (n=95, 84, 91) | -3.09 ± 0.13 | -2.75 ± 0.13 | -2.58 ± 0.13 |
| Month 18 (WP Day 169) (n=41, 31, 32) | -1.54 ± 0.26 | -1.51 ± 0.29 | -1.06 ± 0.29 |
TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity.
| Percentage of participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Month 12 (TP Day 365) | 42.0 (33.15 to 50.89) | 29.3 (21.03 to 37.59) | 25.0 (17.12 to 32.88) |
| Month 18 (WP Day 169) | 10.9 (5.32 to 16.53) | 8.6 (3.51 to 13.73) | 6.9 (2.29 to 11.51) |
TP=treatment period; WP=withdrawal period. The SDAI is the simple linear sum of 5 outcome parameters: swollen joint count (SJC) and tender joint count (TJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SJC is assessed and recorded at each visit, with no swelling=0, swelling=1 (higher score indicates greater swelling). TJC is assessed at each visit through identification of joints that are painful under pressure or to passive motion, with no tenderness=0, tenderness=1 (higher score indicates greater affection due to disease activity)..
| Units on a scale | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| TP Day 29 (n=109, 101, 107) | -13.11 ± 1.33 | -12.14 ± 1.37 | -10.12 ± 1.33 |
| TP Day 57 (n=108, 101, 103) | -18.90 ± 1.25 | -15.83 ± 1.28 | -15.99 ± 1.26 |
| TP Day 85 (n=108, 99, 103) | -24.13 ± 1.16 | -20.51 ± 1.20 | -19.55 ± 1.17 |
| TP Day 113 (n=103, 98, 101) | -25.47 ± 1.12 | -23.56 ± 1.15 | -21.02 ± 1.13 |
| TP Day 141 (n=104, 96, 104) | -27.15 ± 1.10 | -25.99 ± 1.13 | -22.14 ± 1.10 |
| TP Day 169 (n=102, 96, 100) | -28.42 ± 1.08 | -26.20 ± 1.11 | -22.80 ± 1.09 |
| TP Day 197 (n=103, 97, 96) | -29.66 ± 1.01 | -27.57 ± 1.03 | -24.37 ± 1.02 |
| TP Day 225 (n=99, 94, 92) | -30.13 ± 1.04 | -28.39 ± 1.06 | -24.73 ± 1.06 |
| TP Day 253 (n=98, 94, 91) | -31.14 ± 1.04 | -28.10 ± 1.06 | -25.80 ± 1.05 |
| TP 281 (n=96, 93, 89) | -30.98 ± 1.10 | -28.16 ± 1.12 | -26.23 ± 1.12 |
| TP 309 (n=91, 87, 92) | -30.82 ± 1.16 | -27.79 ± 1.18 | -26.36 ± 1.17 |
| TP Day 337 (n=93, 84, 87) | -31.11 ± 1.15 | -29.34 ± 1.19 | -27.26 ± 1.17 |
| TP 365 (n=95, 84, 91) | -31.24 ± 1.17 | -28.88 ± 1.21 | -28.34 ± 1.19 |
| WP Day 29 (n=73, 59, 64) | -30.42 ± 1.32 | -28.05 ± 1.39 | -23.52 ± 1.36 |
| WP Day 57 (n=69, 54, 59) | -27.68 ± 1.59 | -24.17 ± 1.74 | -17.94 ± 1.68 |
| WP Day 85 (n=67, 47, 52) | -22.00 ± 2.18 | -21.55 ± 2.57 | -17.54 ± 2.44 |
| WP Day 169 (n=41, 31, 32) | -17.43 ± 2.82 | -19.13 ± 3.25 | -13.64 ± 3.19 |
HAQ response defined as a reduction of at least 0.3 units from baseline in score on the Health Assessment Questionnaire Disability Index (HAQ-DI), which assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.
| Percentage of participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| TP Day 29 | 42.0 (33.15 to 50.89) | 31.0 (22.62 to 39.45) | 21.6 (14.07 to 29.03) |
| TP Day 57 | 55.5 (46.53 to 64.39) | 44.0 (34.93 to 53.00) | 37.9 (29.10 to 46.76) |
| TP Day 85 | 63.0 (54.35 to 71.70) | 45.7 (36.62 to 54.75) | 41.4 (32.42 to 50.34) |
| TP Day 113 | 63.0 (54.35 to 71.70) | 49.1 (40.04 to 58.24) | 45.7 (36.62 to 54.75) |
| TP Day 141 | 62.2 (53.47 to 70.90) | 51.7 (42.63 to 60.82) | 44.0 (34.93 to 53.00) |
| TP Day 169 | 63.9 (55.23 to 72.50) | 56.0 (47.00 to 65.07) | 41.4 (32.42 to 50.34) |
| TP Day 197 | 66.4 (57.90 to 74.87) | 59.5 (50.55 to 68.42) | 41.4 (32.42 to 50.34) |
| TP Day 225 | 66.4 (57.90 to 74.87) | 57.8 (48.77 to 66.75) | 38.8 (29.93 to 47.66) |
| TP Day 253 | 68.9 (60.59 to 77.22) | 55.2 (46.12 to 64.22) | 45.7 (36.62 to 54.75) |
| TP Day 281 | 64.7 (56.12 to 73.29) | 56.9 (47.88 to 65.91) | 46.6 (37.47 to 55.63) |
| TP Day 309 | 65.5 (57.01 to 74.08) | 56.9 (47.88 to 65.91) | 46.6 (37.47 to 55.63) |
| TP Day 337 | 64.7 (56.12 to 73.29) | 55.2 (46.12 to 64.22) | 46.6 (37.47 to 55.63) |
| TP Day 365 | 67.2 (58.79 to 75.66) | 52.6 (43.50 to 61.67) | 44.0 (34.93 to 53.00) |
| WP Day 29 | 52.1 (43.13 to 61.08) | 39.7 (30.75 to 48.56) | 37.1 (28.28 to 45.86) |
| WP Day 57 | 43.7 (34.79 to 52.61) | 34.5 (25.83 to 43.13) | 26.7 (18.67 to 34.78) |
| WP Day 85 | 39.5 (30.71 to 48.28) | 28.4 (20.24 to 36.66) | 23.3 (15.59 to 30.97) |
| WP Day 169 | 22.7 (15.16 to 30.21) | 16.4 (9.64 to 23.11) | 10.3 (4.80 to 15.89) |
| WP Day 253 | 15.1 (8.69 to 21.56) | 9.5 (4.15 to 14.81) | 6.9 (2.29 to 11.51) |
| WP Day 365 | 10.1 (4.67 to 15.49) | 6.9 (2.29 to 11.51) | 5.2 (1.14 to 9.20) |
The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.
| Units on a scale | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| TP Day 29 (n=104, 103, 91) | -0.33 ± 0.05 | -0.21 ± 0.05 | -0.09 ± 0.05 |
| TP Day 57 (n=102, 100, 93) | -0.48 ± 0.05 | -0.38 ± 0.05 | -0.32 ± 0.05 |
| TP Day 85 (n=105, 97, 88) | -0.64 ± 0.05 | -0.45 ± 0.05 | -0.40 ± 0.05 |
| TP Day 113 (n=105, 98, 90) | -0.67 ± 0.05 | -0.55 ± 0.05 | -0.50 ± 0.05 |
| TP Day 141 (n=100, 98, 88) | -0.72 ± 0.05 | -0.53 ± 0.05 | -0.46 ± 0.06 |
| TP Day 169 (n=95, 95, 85) | -0.74 ± 0.05 | -0.59 ± 0.05 | -0.52 ± 0.06 |
| TP Day 197 (n=99, 96, 83) | -0.78 ± 0.05 | -0.62 ± 0.06 | -0.54 ± 0.06 |
| TP Day 225 (n=98, 95, 83) | -0.79 ± 0.06 | -0.67 ± 0.06 | -0.56 ± 0.06 |
| TP Day 253 (n=96, 91, 84) | -0.82 ± 0.05 | -0.65 ± 0.06 | -0.63 ± 0.06 |
| TP Day 281 (n=90, 93, 81) | -0.82 ± 0.06 | -0.65 ± 0.06 | -0.62 ± 0.06 |
| TP Day 309 (n=89, 88, 82) | -0.81 ± 0.06 | -0.67 ± 0.06 | -0.66 ± 0.06 |
| TP Day 337 (n=88, 85, 80) | -0.84 ± 0.06 | -0.70 ± 0.06 | -0.70 ± 0.06 |
| TP Day 365 (n=90, 82, 77) | -0.87 ± 0.06 | -0.73 ± 0.06 | -0.72 ± 0.06 |
| WP Day 29 (n=70, 55, 55) | -0.85 ± 0.06 | -0.67 ± 0.07 | -0.63 ± 0.07 |
| WP Day 57 (n=66, 53, 54) | -0.67 ± 0.07 | -0.58 ± 0.08 | -0.39 ± 0.08 |
| WP Day 85 (n=65, 45, 46) | -0.54 ± 0.08 | -0.48 ± 0.09 | -0.37 ± 0.09 |
| WP Day 169 (n=34, 28, 26) | -0.52 ± 0.10 | -0.49 ± 0.11 | -0.33 ± 0.12 |
TP=treatment period; WP=withdrawal period. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life (QOL) and comprises 8 domains, including 4 physical (physical health, bodily pain, physical functioning and physical role limitations) and 4 mental (mental health, vitality, social functioning, and emotional role limitation) subscales. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QOL (0=Poorest Health; 100=Best Health). Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
| Units on a scale | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| PCS score TP Day 169 (n=106, 95, 96) | 11.68 ± 0.82 | 9.16 ± 0.86 | 7.47 ± 0.85 |
| PCS score TP Day 365 (n=94, 88, 91) | 13.91 ± 0.93 | 10.23 ± 0.97 | 10.92 ± 0.95 |
| PCS score WP Day 169 (n=48, 36, 37) | 6.16 ± 1.45 | 4.59 ± 1.65 | 6.27 ± 1.63 |
| MCS score TP Day 169 (n=106, 95, 96) | 6.11 ± 0.92 | 3.99 ± 0.97 | 4.69 ± 0.95 |
| MCS score TP Day 365 (n=94, 88, 91) | 7.67 ± 1.04 | 5.48 ± 1.08 | 7.23 ± 1.06 |
| MCS score WP Day 169 (n=48, 36, 37) | 2.75 ± 1.44 | 4.36 ± 1.64 | 2.23 ± 1.63 |
TP=treatment period; WP=withdrawal period. Change from Baseline=Postbaseline-baseline value. MRI was used to assess joint damage progression at Months 6, 12, and 18. If \>20% of joints with a missing score for a parameter (erosion, osteitis, and synovitis), the MRI score of each parameter was considered missing. If ≤20% of joints had a missing score for a parameter, the MRI score for that parameter from the missing joints was carried forward from the previous MRI assessment, or carried backward from the next MRI assessment, if missing score occurred at baseline. MRI total score ranged from 0 (best outcome) to 4 (worst outcome). A gadolinium-enhanced MRI of the dominant hand-wrist was performed on all randomized patients at 5 points. The hand/wrist assessed to have more synovitis was selected initially and used for all subsequent evaluations. The MRI examination was standardized to ensure sufficient image quality for the evaluation of radiographic progression of rheumatoid arthritis.
| Units on a scale | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Osteitis TP Day 169 (n=93, 94, 89) | -2.03 ± 0.47 | -1.13 ± 0.47 | -0.73 ± 0.48 |
| Osteitis TP Day 365 (n=83, 74, 78) | -2.32 ± 0.46 | -1.30 ± 0.46 | -0.90 ± 0.46 |
| Osteitis WP Day 169 (n=31, 30, 25) | -1.94 ± 0.88 | 0.98 ± 0.89 | -0.33 ± 0.96 |
| Erosion TP Day 169 (n=93, 94, 89) | 0.26 ± 0.28 | 1.15 ± 0.28 | 1.15 ± 0.28 |
| Erosion TP Day 365 (n=83, 74, 78) | 0.34 ± 0.35 | 1.57 ± 0.36 | 1.56 ± 0.36 |
| Erosion WP Day 169 (n=31, 30, 25) | 0.20 ± 0.47 | 2.16 ± 0.48 | 1.89 ± 0.50 |
| Synovitis TP Day 169 (n=93, 94, 89) | -1.82 ± 0.21 | -0.93 ± 0.21 | -0.78 ± 0.21 |
| Synovitis TP Day 365 (n=83, 74, 78) | -2.38 ± 0.29 | -1.36 ± 0.30 | -0.77 ± 0.30 |
| Synovitis WP Day 169 (n=31, 30, 25)) | -1.71 ± 0.45 | -0.95 ± 0.45 | -0.71 ± 0.49 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.
| Participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Deaths | 0 | 0 | 2 |
| SAEs | 8 | 14 | 9 |
| Related SAEs | 3 | 3 | 1 |
| Discontinuations due to SAEs | 2 | 5 | 3 |
| Related AEs | 53 | 48 | 51 |
| Discontinuations due to AEs | 4 | 8 | 5 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. AEs of special interest are events potentially associated with the drug or disease under study.
| Participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Infections | 68 | 64 | 69 |
| Malignancy | 1 | 2 | 1 |
| Autoimmune disorders (prespecified) | 1 | 2 | 3 |
| Local injection site reactions (prespecified) | 2 | 0 | 0 |
Lower limit of normal (LLN); Upper limit of normal (ULN); Pretreatment (preRX). Criteria for marked abnormality: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.
| Participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Platelet count (high) (n=119, 116, 115) | 2 | 0 | 0 |
| Potassium, serum (low) | 1 | 1 | 1 |
| Blood urea nitrogen (high) | 4 | 1 | 2 |
| Creatinine (high) | 2 | 1 | 3 |
| Alanine aminotransferase (ALT)(high) | 3 | 0 | 2 |
| Aspartate aminotransferase (AST)(high) | 2 | 0 | 1 |
| G-glutamyl transferase (GGT) (high) | 3 | 1 | 1 |
| Glucose, fasting (low) (n=78, 72, 75) | 2 | 0 | 2 |
| Glucose, fasting (high) (n=78, 72, 75) | 1 | 2 | 1 |
| Glucose, serum (low) (n=84, 78, 75) | 5 | 6 | 2 |
| Glucose, serum (high) (n=84, 78, 75) | 1 | 4 | 3 |
| Uric acid (high) | 0 | 1 | 0 |
| Albumin (low) | 1 | 1 | 4 |
| Hemoglobin (low) (n=119, 116, 115) | 0 | 2 | 0 |
| Hematocrit (low) (n=119, 116, 115) | 0 | 2 | 0 |
WP=withdrawal period. Remission defined as DAS28-CRP\<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.). Percentage= number of participants with remission divided by number of participants who were analyzed (all treated participants who were in remission at end of treatment period and entered the Withdrawal Period)
| percentage of participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| WP Day 29 | 73.3 (65.46 to 85.23) | 72.0 (59.55 to 84.45) | 54.7 (41.32 to 68.12) |
| WP Day 57 | 58.9 (47.62 to 70.19) | 56.0 (42.24 to 69.76) | 32.1 (19.51 to 44.64) |
| WP Day 85 | 42.5 (31.13 to 53.80) | 40.0 (26.42 to 53.58) | 35.8 (22.94 to 48.76) |
| WP Day 169 | 26.0 (15.96 to 36.09) | 30.0 (17.30 to 42.70) | 17.0 (6.87 to 27.09) |
| WP Day 253 | 20.5 (11.28 to 29.82) | 22.0 (10.52 to 33.48) | 20.8 (9.84 to 31.67) |
| WP Day 365 | 12.3 (4.79 to 19.87) | 14.0 (4.38 to 23.62) | 11.3 (2.79 to 19.85) |
TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity. Percent=number with remission/number evaluated (ITT)
| percentage of participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| TP Day 29 | 4.2 (1.38 to 9.53) | 3.4 (0.95 to 8.59) | 1.7 (0.21 to 6.09) |
| TP Day 57 | 9.2 (4.71 to 15.94) | 6.0 (2.46 to 12.04) | 1.7 (0.21 to 6.09) |
| TP Day 85 | 17.6 (10.80 to 24.50) | 8.6 (3.51 to 13.73) | 6.0 (1.70 to 10.37) |
| TP Day 113 | 23.5 (15.91 to 31.15) | 17.2 (10.37 to 24.12) | 7.8 (2.89 to 12.63) |
| TP Day 141 | 31.9 (23.56 to 40.31) | 23.3 (15.59 to 30.97) | 10.3 (4.80 to 15.89) |
| TP Day 169 | 31.1 (22.78 to 39.41) | 20.7 (13.32 to 28.06) | 11.2 (5.47 to 16.95) |
| TP Day 197 | 33.6 (25.13 to 42.10) | 21.6 (14.07 to 29.03) | 12.9 (6.82 to 19.04) |
| TP Day 225 | 38.7 (29.91 to 47.40) | 25.9 (17.89 to 33.83) | 14.7 (8.22 to 21.09) |
| TP Day 253 | 37.8 (29.10 to 46.53) | 25.0 (17.12 to 32.88) | 13.8 (7.52 to 20.07) |
| TP Day 281 | 37.8 (29.10 to 46.53) | 26.7 (18.67 to 34.78) | 18.1 (11.10 to 25.11) |
| TP Day 309 | 40.3 (31.52 to 49.15) | 26.7 (18.67 to 34.78) | 19.0 (11.83 to 26.10) |
| TP Day 337 | 41.2 (32.33 to 50.02) | 31.0 (22.62 to 39.45) | 19.0 (11.83 to 26.10) |
| TP Day 365 | 42.0 (33.15 to 50.89) | 29.3 (21.03 to 37.59) | 25.0 (17.12 to 32.88) |
| WP Day 29 | 38.7 (29.91 to 47.40) | 26.7 (18.67 to 34.78) | 14.7 (8.22 to 21.09) |
| WP Day 57 | 26.9 (18.92 to 34.86) | 20.7 (13.32 to 28.06) | 10.3 (4.80 to 15.89) |
| WP Day 85 | 21.0 (13.69 to 28.33) | 15.5 (8.93 to 22.11) | 14.7 (8.22 to 21.09) |
| WP Day 169 | 11.8 (5.98 to 17.55) | 9.5 (4.15 to 14.81) | 6.9 (2.29 to 11.51) |
| WP Day 253 | 11.8 (5.98 to 17.55) | 9.5 (4.15 to 14.81) | 7.8 (2.89 to 12.63) |
| WP Day 365 | 6.7 (2.22 to 11.22) | 4.3 (0.61 to 8.01) | 4.3 (0.61 to 8.01) |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Includes data up to last active dose date +56 days if the participant discontinued the Treatment Period or did not enter the Withdrawal Period, up to the day of discontinuation in the Withdrawal Period for participants discontinuing the Withdrawal Period without entering the Re-exposure Period (RP), up to Day 729 visit (Month 24) for participants who complete the Withdrawal Period, and up to 56 days post last active dose in Re-exposure Period for participants entering the Re-exposure Period.
| participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Death | 0 | 0 | 2 |
| SAE | 11 | 15 | 15 |
| Discontinued Due to AE | 4 | 8 | 7 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes events with an onset date on or after 57 days post last dosing day (active abatacept or active MTX whichever is the later) in the Treatment Period and up to end of Withdrawal Period. Treatment groups represent treatment received during the Treatment Period.
| participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Infections | 8 | 6 | 10 |
| Malignancy | 1 | 0 | 1 |
| Autoimmune disorders (prespecified) | 0 | 0 | 1 |
| Local injection site reactions(prespecified) | 0 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes data up to 56 days post the last dosing day (active abatacept or active MTX, whichever is the later) in the Re-exposure Period. Treatment groups represent Treatment received during Treatment Period.
| participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Infections | 17 | 8 | 12 |
| Malignancy | 0 | 0 | 0 |
| Autoimmune Disorders (prespecified) | 0 | 0 | 0 |
| Local Injection site reactions (prespecified) | 0 | 0 | 0 |
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase (GGT) (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.
| participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Hemoglobin Low (n=60, 52, 48) | 1 | 2 | 0 |
| Creatinine High (n=60, 52, 48) | 1 | 2 | 2 |
| Alanine aminotransferase (ALT) High (n=60, 52, 48) | 1 | 0 | 0 |
| GGT High (n=60, 52, 48) | 1 | 0 | 0 |
| Fasting Glucose High (30, 28, 25) | 0 | 2 | 1 |
| Glucose Low (n=36,31,27) | 5 | 3 | 0 |
| Glucose High (n=36, 31, 27) | 0 | 1 | 1 |
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (\*10\^9 c/µL) \<0.67\*LLN or \>1.5\*ULN, or if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; potassium, serum (mEq) \<0.9\*LLN or \>1.1\*ULN, or if preRX \<LLN, use \<0.9\*preRX or \>ULN if preRX\>ULN, use \>1.1\*preRX or \<LLN; blood urea nitrogen (mg/dL) \>2\*preRX; creatinine (mg/dL) \>1.5\*preRX; ALT (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; AST (U/L) \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALP (U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; G-glutamyl transferase U/L) \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; glucose, fasting (mg/dL) \<0.8\*LLN or \>1.5\*ULN, or if preRX\<LLN use \<0.8\*preRX or \>ULN if preRX \>ULN, use \>2.0\*preRX or OR \<LLN; glucose, serum (mg/dL) \<65 or \>220; uric acid (mg/dL)\>1.5\*ULN, or if preRX, use \>2\*preRX; albumin (g/dL) \<0.9\*LLN, or if preRX\<LLN, use \<0.75\*preRX; hemoglobin (g/dL)\>3 decrease from preRX; hematocrit (%) \< 0.75\*preRX.
| participants | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| Hematocrit Low (n=55,47,43) | 0 | 1 | 0 |
| Hemoglobin Low (n=55,48, 43) | 0 | 2 | 0 |
| Creatinine High (n=55, 48, 43) | 0 | 1 | 0 |
| ALT High (n=55, 48, 43) | 2 | 0 | 2 |
| ALP High (n=55, 48, 43) | 1 | 0 | 0 |
| AST High (n=55, 48, 43) | 2 | 0 | 1 |
| GGT High (n=55, 48, 43) | 2 | 0 | 1 |
| Fasting Glucose Low (n=33, 32, 28) | 1 | 0 | 0 |
| Fasting Glucose High (n=33, 32, 28) | 0 | 2 | 1 |
| Glucose Low (n=27,24,18) | 0 | 2 | 0 |
| Glucose High (n=27,24,18) | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | — | 11/119 (9.2%) | 81/119 (68.1%) |
| Abatacept, 125 mg, Plus Methotrexate Placebo | — | 15/116 (12.9%) | 64/116 (55.2%) |
| Methotrexate, 2.5 mg, Plus Abatacept Placebo | — | 15/116 (12.9%) | 78/116 (67.2%) |
| Event | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 3/119 | 1/116 | 2/116 |
| Carotid artery occlusionNervous system disorders | 0/119 | 1/116 | 0/116 |
| CholelithiasisHepatobiliary disorders | 0/119 | 0/116 | 1/116 |
| Endometrial disorderReproductive system and breast disorders | 0/119 | 1/116 | 0/116 |
| Small intestinal obstructionGastrointestinal disorders | 0/119 | 0/116 | 1/116 |
| Urinary tract infectionInfections and infestations | 0/119 | 0/116 | 1/116 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 0/116 | 1/116 |
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 0/116 | 1/116 |
| Bowen's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 1/116 | 0/116 |
| DepressionPsychiatric disorders | 0/119 | 1/116 | 0/116 |
| Event | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 28/119 | 20/116 | 22/116 |
| Upper respiratory tract infectionInfections and infestations | 15/119 | 15/116 | 20/116 |
| NauseaGastrointestinal disorders | 18/119 | 8/116 | 16/116 |
| Urinary tract infectionInfections and infestations | 14/119 | 15/116 | 15/116 |
| BronchitisInfections and infestations | 8/119 | 6/116 | 10/116 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/119 | 9/116 | 7/116 |
| InfluenzaInfections and infestations | 5/119 | 9/116 | 6/116 |
| SinusitisInfections and infestations | 9/119 | 4/116 | 2/116 |
| HeadacheNervous system disorders | 8/119 | 8/116 | 7/116 |
| DiarrhoeaGastrointestinal disorders | 5/119 | 8/116 | 4/116 |
All randomized patients who received at least 1 dose of double-blind study medication in the Treatment Period
| Age, Continuous(Years) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| Mean | 46.4 ± 13.20 | 45.4 ± 11.92 | 49.1 ± 12.36 | 47.0 ± 12.57 |
| Sex: Female, Male(Participants) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| Female | 95 | 89 | 89 | 273 |
| Male | 24 | 27 | 27 | 78 |
| Race/Ethnicity, Customized(Participants) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| White | 100 | 95 | 102 | 297 |
| Asian | 14 | 13 | 9 | 36 |
| Black/African American | 2 | 4 | 2 | 8 |
| American Indian/Alaska native | 1 | 1 | 1 | 3 |
| Other | 2 | 3 | 2 | 7 |
| Duration of rheumatoid arthritis(Years) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| Mean | 0.58 ± 0.500 | 0.59 ± 0.522 | 0.50 ± 0.488 | 0.56 ± 0.504 |
| Disease Activity Score 28 based on C-reactive protein (DAS28-CRP)(Units on a scale) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| Mean | 5.528 ± 1.2501 | 5.463 ± 1.1493 | 5.315 ± 1.3330 | 5.435 ± 1.2465 |
| Health Assessment Questionnaire Disability Index (HAQ-DI) score(Units on a scale) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| Mean | 1.452 ± 0.6778 | 1.419 ± 0.6587 | 1.383 ± 0.6493 | 1.419 ± 0.6609 |
| Rheumatoid factor status(Participants) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| Positive | 113 | 111 | 110 | 334 |
| Negative | 6 | 5 | 6 | 17 |
| Tender joint count(Joints) | Abatacept, 125 mg, Plus Methotrexate, 2.5 mg | Abatacept, 125 mg, Plus Methotrexate Placebo | Methotrexate, 2.5 mg, Plus Abatacept Placebo | Total |
|---|---|---|---|---|
| Mean | 24.3 ± 15.74 | 23.9 ± 14.47 | 21.7 ± 14.00 | 23.3 ± 14.77 |
1 further baseline measures are reported on the registry.
The record gives a start of Dec 2010, a primary completion of Sep 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abatacept · Methotrexate